Skip to main content
TipRanks
Go Ultimate75% OFF

Cerenome (XMP1) Stock Price & Analysis

3 Followers

XMP1 Stock Chart & Stats

€0.64€0.02(2.89%)
At close: 5:30 PM GMT+1
€1€2€3Aug 17Aug 27Sep 21Sep 30Oct 14Nov 9
Day’s Range
EUR 0.64 - EUR 0.64
52-Week Range
EUR 0.44 - EUR 28.15
Previous Close
EUR 0.62
Volume
N/A
Average Volume (3M)
57
Market Cap
EUR 6.54M
Enterprise Value
EUR 13.26M
Total Cash (Recent Filing)
EUR 4.87M
Total Debt (Recent Filing)
EUR 3.98M
Price to Earnings (P/E)
―
Beta
1.14
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Gross Margin

The roughly 90% TTM gross margin indicates strong product-level economics and suggests the core offering can generate substantial contribution after direct costs. If revenue scales, this margin profile could support operating leverage, although current overhead still prevents profitability.

Commercial Expansion

Planned sales expansion, billing activity, and Medicare reimbursement create identifiable pathways to broaden CNSide revenue. These milestones could improve market access and commercial execution over the next several quarters, making growth less dependent on existing activity.

Funding Runway

Extending the expected cash runway well into 2028 gives Cerenome additional time to develop its CNS oncology platform, pursue commercialization, and reach operational milestones. More funding continuity can reduce near-term disruption risk while sales initiatives mature.

Bears Say

Declining Revenue

Very small and declining revenue shows that Cerenome has not yet achieved meaningful commercial scale. Persistent top-line contraction limits operating leverage, makes fixed spending harder to absorb, and increases dependence on successful future commercialization milestones.

Losses And Cash Burn

Large losses alongside deeply negative operating and free cash flow indicate that the business is consuming substantial capital relative to its revenue base. Unless spending falls or revenue scales materially, continued cash usage will constrain flexibility and require further funding.

Balance Sheet Pressure

Negative equity weakens financial resilience, while secured financing adds contractual repayment pressure and places substantially all assets behind creditors. The combination can restrict future capital allocation and increase refinancing or dilution risk if commercialization takes longer than planned.

Cerenome News

XMP1 FAQ

What was Cerenome’s price range in the past 12 months?
Cerenome lowest stock price was €0.44 and its highest was €28.15 in the past 12 months.
What is Cerenome’s market cap?
Cerenome’s market cap is €6.54M.
When is Cerenome’s upcoming earnings report date?
Cerenome’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 101 days.
How were Cerenome’s earnings last quarter?
Cerenome released its earnings results on Nov 13, 2026. The company reported -€1.034 earnings per share for the quarter, missing the consensus estimate of -€0.865 by -€0.17.
Is Cerenome overvalued?
According to Wall Street analysts Cerenome’s price is currently Undervalued.
Does Cerenome pay dividends?
Cerenome does not currently pay dividends.
What is Cerenome’s EPS estimate?
Cerenome’s EPS estimate is -0.78.
How many shares outstanding does Cerenome have?
Cerenome has 7,589,774 shares outstanding.
What happened to Cerenome’s price movement after its last earnings report?
Cerenome reported an EPS of -€1.034 in its last earnings report, missing expectations of -€0.865. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Cerenome?
Currently, no hedge funds are holding shares in DE:XMP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology